GILD Stock Recent News
GILD LATEST HEADLINES
Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
In the most recent trading session, Gilead Sciences (GILD) closed at $69.94, indicating a +0.75% shift from the previous trading day.
With strong market performance in recent periods, finding stocks priced at a discount can be challenging. However, examining stocks at 52-week lows may identify equities valued below their potential.
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2024 financial results and guidance will be released on Thursday, April 25, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's first quarter 2024 financial results and provide a business update. A live webcast will be available on the Investor Relations section of www.gilead.com and will be archived the.
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
My April Dividend Stock Buys With Yields Up To 12%
When it comes to finding the best value stocks to buy, sometimes you have to go against the grain. That is, dive into stocks that have fallen out of favor with the market, to assess whether investor sentiment is on the money, or an overreaction.
Gilead Sciences has a strong track record in curing Hepatitis C and a successful HIV business. The company has struggled with acquisitions but is expected to generate strong shareholder returns. Gilead Sciences has new businesses and milestones planned for 2024.
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.